George Soros’s BioMarin Pharmaceuticals BMRN Stock Holding History

George Soros’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-156,053	Closed	-$12.8M	–	191
2024 Q2	$12.8M	Buy	156,053 +153	+0.1%	+$12.7K	0.23%	102
2024 Q1	$13.6M	Buy	+155,900	New	+$14M	0.23%	104
2017 Q3	–	Sell	-2,500	Closed	-$227K	–	234
2017 Q2	$227K	Buy	+2,500	New	+$227K	﹤0.01%	188
2016 Q4	–	Sell	-5,734	Closed	-$531K	–	219
2016 Q3	$531K	Buy	+5,734	New	+$540K	0.01%	163

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

George Soros's BMRN Position: Q3 2024 in Review

George Soros sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 156,053 shares — an estimated $12.8M sold.

George Soros first reported a position in BMRN in Q3 2016 and held it in 4 quarters. The position peaked at $13.6M in Q1 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

George Soros reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
George Soros sold 156,053 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $12.8M.
George Soros first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 4 quarters.
George Soros's BioMarin Pharmaceuticals position peaked at $13.6M in Q1 2024.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Soros Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.